IP Library › Granted Patent US 9,999,641
Granted Patent B2
US 9,999,641 · App. 15/630,088 · Granted Jun 19, 2018

Treatment of clostridium difficile infection

Inventors: Jessica Schneider (Cambridge, MA); Yun-Gi Kim (Watertown, MA); Bernat Olle (Cambridge, MA); Shilpa Reddy (Watertown, MA); Jason Norman (North Weymouth, MA); Juan Patarroyo (Lexington, MA)
Assignee: Vedanta Biosciences, Inc.
A61K35/747A61K9/0053A61K9/48A61K35/74A61K35/742
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,999,641
App. No.
15/630,088
Granted
Jun 19, 2018
Kind
B2
Abstract

Provided herein are compositions and methods for the treatment or prevention of pathogenic infections.

Claims (8)

1. A pharmaceutical composition comprising a purified bacterial mixture consisting of bacterial strains comprising 16S rDNA sequences of at least 97% sequence identity to SEQ ID NO:10, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:20, and SEQ ID NO:21; wherein the bacterial strains are lyophilized.

2. The pharmaceutical composition of claim 1 , wherein one or more of the bacterial strains are spore-formers.

3. The pharmaceutical composition of claim 1 , wherein the bacterial strains originate from more than one human donor.

4. The pharmaceutical composition of claim 1 , further comprising a pharmaceutically acceptable excipient.

5. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated for oral administration.

6. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is in the form of a capsule.

7. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated for delivery to the colon.

8. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition further comprises one or more enteric polymers.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Apr 24, 2023
From: OXFORD FINANCE LLC
To: VEDANTA BIOSCIENCES, INC.
Reel/Frame 063440/0569 →
SECURITY INTEREST Recorded Apr 21, 2023
From: VEDANTA BIOSCIENCES, INC.
To: ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE
Reel/Frame 063406/0052 →
SECURITY INTEREST Recorded Dec 12, 2022
From: VEDANTA BIOSCIENCES, INC.
To: OXFORD FINANCE LLC
Reel/Frame 062115/0411 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 22, 2017
From: SCHNEIDER, JESSICA; KIM, YUN-GI; OLLE, BERNAT; REDDY, SHILPA; NORMAN, JASON; PATARROYO, JUAN
To: VEDANTA BIOSCIENCES, INC.
Reel/Frame 043634/0773 →
Continuity (3)
Continuation PCTUS2017037498 · Jun 14, 2017
Provisional Application 62349914 · Jun 14, 2016
Related Publication 20170354697A1 · Dec 14, 2017